NCT06149481 2026-06-05Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)National Institutes of Health Clinical Center (CC)Phase 1/2 Recruiting60 enrolled